SEC Form 4 · accession 0001193125-26-261660
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard D Francis
Officer — President and CEO
Period of report
Jun 5, 2026
Accepted (ET)
Jun 8, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jun 5, 2026 | M | 13,043 | — | A | 1,183,682 | D | |
| Ordinary SharesF1,F4 | Jun 5, 2026 | S | 6,153 | $34.35 | D | 1,177,529 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F5,F1 | — | Jun 5, 2026 | M | 13,043 | D | — | — | Ordinary Shares | 13,043 | 39,130 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F3The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.
- F4Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- F5Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029.